Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cell therapy
Biotech
BioCardia rejigs phase 3 heart failure data to find a path
BioCardia’s data safety board already warned that the phase 3 CardiAMP cell therapy heart failure trial was not going to make the primary endpoint.
Annalee Armstrong
Mar 4, 2024 10:15am
Kyverna overshoots raised IPO expectations with $319M offering
Feb 8, 2024 8:24am
Neurona knocks out $120M raise a year after layoffs
Feb 8, 2024 8:00am
Regeneron to fill gaps in obesity, break ground in cell therapy
Feb 2, 2024 10:25am
Takeda drops cancer candidates amid shifting treatment landscape
Feb 2, 2024 5:33am
Kyverna eyes $180M IPO haul to fund autoimmune CAR-T trials
Feb 1, 2024 9:45am